SEL 068

Drug Profile

SEL 068

Alternative Names: Immunomodulatory nanoparticle vaccine for smoking cessation - Selecta Biosciences; SEL-068; tSVP™ for smoking cessation and relapse prevention - Selecta Biosciences

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Selecta Biosciences
  • Class Drug withdrawal therapies; Smoking cessation therapies; Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Smoking withdrawal

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Smoking-withdrawal(Prevention of relapse, In volunteers) in Belgium (SC, Injection)
  • 06 May 2014 Selecta Biosciences completes a phase I trial in in volunteers for Smoking withdrawal in Belgium (NCT01478893)
  • 21 Nov 2011 Phase-I clinical trials in Smoking withdrawal in Belgium (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top